Complicated Urinary Tract Infections Due To Enterobacteriaceae Therapeutics
1. Zemdri patent expiration
Treatment: Method of using plazomicin to treat bacterial infections
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8383596 | CIPLA USA | Antibacterial aminoglycoside analogs |
Jun, 2031
(5 years from now) | |
| US9688711 | CIPLA USA | Antibacterial aminoglycoside analogs |
Nov, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9266919 | CIPLA USA | Antibacterial aminoglycoside analogs |
Nov, 2028
(2 years from now) | |
| US8822424 | CIPLA USA | Antibacterial aminoglycoside analogs |
Nov, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 25, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 25, 2028 |
Drugs and Companies using PLAZOMICIN SULFATE ingredient
NCE-1 date: 26 June, 2027
Market Authorisation Date: 25 June, 2018
Dosage: SOLUTION
More Information on Dosage
ZEMDRI family patents
